secwatch.observer — SEC 8-K summary
======================================

Issuer:     Fulgent Genetics, Inc. (FLGT)
CIK:        0001674930
Form:       8-K
Filed at:   2022-04-26T23:59:59+00:00
Accession:  0001564590-22-015730
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Fulgent Genetics completes $170M acquisition of Symphony Buyer via merger
-------------------------------------------------------------------------

- Total purchase price of approximately $170 million, subject to customary adjustments for closing cash, indebtedness, working capital, and expenses.
- Acquisition closed on April 26, 2022; Symphony becomes wholly owned subsidiary of Fulgent Genetics.
- Deal originally announced via merger agreement dated April 16, 2022; stockholders of Symphony consented to the merger.
- Consideration includes upfront cash per share plus contingent rights to escrow and post-closing adjustments.
- Merger was effected through merger of a Fulgent subsidiary (Merger Sub) into Symphony, with Symphony surviving.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1674930/000156459022015730/0001564590-22-015730-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1674930/000156459022015730/flgt-8k_20220426.htm
  HTML page:      https://secwatch.observer/filing/0001564590-22-015730

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer